KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Abbott Laboratories (ABT) Debt to Equity (2016 - 2025)

Abbott Laboratories (ABT) has disclosed Debt to Equity for 17 consecutive years, with $0.25 as the latest value for Q4 2025.

  • Quarterly Debt to Equity fell 17.33% to $0.25 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.25 through Dec 2025, down 17.33% year-over-year, with the annual reading at $0.25 for FY2025, 17.33% down from the prior year.
  • Debt to Equity hit $0.25 in Q4 2025 for Abbott Laboratories, down from $0.25 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $151.94 in Q1 2024 to a low of -$10.31 in Q3 2023.
  • Historically, Debt to Equity has averaged $26.2 across 5 years, with a median of $0.28 in 2025.
  • Biggest five-year swings in Debt to Equity: tumbled 113.13% in 2023 and later soared 21915.65% in 2024.
  • Year by year, Debt to Equity stood at $81.31 in 2021, then tumbled by 102.56% to -$2.08 in 2022, then rose by 10.12% to -$1.87 in 2023, then soared by 115.83% to $0.3 in 2024, then decreased by 17.33% to $0.25 in 2025.
  • Business Quant data shows Debt to Equity for ABT at $0.25 in Q4 2025, $0.25 in Q3 2025, and -$2.04 in Q2 2025.